国家卫健委、国家中医药局、国家疾控局、中央军委后勤保障部联合修订发布《医疗机构麻醉药品和精神药品管理规定》，将于2026年10月1日起实施1。新规共11章73条，适用范围从原有的药用类麻醉药品、第一类精神药品扩大至全部药用类麻精药品1。
修订后的规定重点细化了采购、储存、开具、使用、回收、销毁等关键环节的管理要求1。新规要求医师为患者开具麻精药品处方时，应充分告知相关药品的法律属性1。对于未成年患者，医疗机构在开具麻精药品处方前需取得监护人的书面知情同意1。此外，修订还强化了信息化管理1。
The National Health Commission and other government departments have revised and issued the Regulations on the Management of Anesthetic and Psychotropic Drugs in Medical Institutions, which will take effect on October 1, 2026.1 The updated regulations expand the scope of application to cover all pharmaceutical-grade anesthetic and psychotropic drugs, moving beyond the previous focus on anesthetic drugs and first-category psychotropic substances.1
The new rules introduce stricter requirements across key operational areas, including procurement, storage, dispensing, use, recovery, and disposal of controlled substances.1 Among the enhanced provisions is a requirement that physicians must fully inform patients of the legal implications of anesthetic and psychotropic drugs when issuing prescriptions.1 For minors, prescribers must obtain written informed consent from guardians before dispensing such medications.1 The revised regulations, comprising 11 chapters and 73 articles in total, also strengthen information management systems to improve oversight and compliance.1
评论
还没有评论，欢迎留下第一条。